Your session is about to expire
← Back to Search
Other
NT-101 Eye Drops for Age-Related Macular Degeneration
Phase 1 & 2
Waitlist Available
Research Sponsored by NexThera Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subject who is male or female ≥ 50 years of age at Screening
Choroidal neovascularization (CNV) lesions secondary to AMD affecting the central subfield in the study eye that meets specific criteria
Must not have
Active intraocular or periocular infection or inflammation in either eye on Screening
History of vitrectomy in the study eye
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4 compared to baseline
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new eye drop called NT-101 for people with wet age-related macular degeneration.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 50 years old or older.
Select...
My eye condition is due to AMD and affects my central vision.
Select...
My vision loss is mainly due to wet AMD.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have an eye infection or inflammation.
Select...
I have had a vitrectomy in one of my eyes.
Select...
I haven't had eye surgery in the last 3 months nor plan to in the next 6 months.
Select...
I have not had a stroke or heart attack in the last 6 months.
Select...
I have not had major surgery in the last 3 months.
Select...
I have other eye conditions that could affect my vision.
Select...
I have had eye inflammation not related to normal surgery recovery.
Select...
I do not have uncontrolled glaucoma.
Select...
My recent tests show I have certain illnesses.
Select...
I have clear vision in my study eye with no issues blocking a view of the retina.
Select...
I have had a retinal detachment or surgery for it in one eye.
Select...
I have been treated for AMD with Beovu® or photodynamic therapy in the affected eye.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 4 compared to baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4 compared to baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change in CST in the Study Eye
Change in ETDRS BCVA Letter Score in the Study Eye
Change in IOP in the Study Eye
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: NT-101 0.2 mMExperimental Treatment1 Intervention
Group II: NT-101 0.05 mMExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
NexThera Co., Ltd.Lead Sponsor
KCRN Research, LLCIndustry Sponsor
9 Previous Clinical Trials
449 Total Patients Enrolled